Adagrasibu Drug Encyclopedia Introduction to Targeted Drugs

Adagrasib, this innovative drug, was recently approved by the USFDA for the treatment of specific cancers, bringing new treatment opportunities to many patients. Adagrasiib has shown significant therapeutic effects in patients with non-small cell lung cancer (NSCLC), especially those whose cancer has spread or cannot be surgically removed and whose tumors have the KRAS G12C mutation. These patients must have tried at least one systemic therapy before receiving treatment. In the treatment of non-small cell lung cancer, adagrasib is used as a single drug to help patients control their disease and improve their quality of life through targeted therapy targeting the KRAS G12C mutation.

In addition, adagrasib also plays an important role in the treatment of metastatic colorectal cancer (CRC). For colorectal cancer patients whose cancer has spread or cannot be surgically removed and whose tumors have KRAS G12C mutations, the combination of adagrasiib and cetuximab provides patients with a new treatment strategy. These patients must have already tried fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy before receiving adagrasiib. Through combined treatment, adagrasib is expected to help patients prolong their survival and reduce their pain.

The KRAS gene produces a protein that acts like a switch, controlling cell growth and cell death. Abnormalities in the KRAS G12C gene may cause cancer cells to grow and spread in the body. Adagrasiib helps stop tumor growth by inhibiting KRAS G12C.

In general, as a targeted drug, adagrasib has brought new treatment options to cancer patients with KRAS G12C mutations with its unique mechanism of action and good clinical effects. Its emergence not only provides patients with more treatment opportunities, but also demonstrates the continuous progress and innovation of modern medicine in the field of cancer treatment.